FDA Approval Alert: The Need-to-Know | Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

In April 2024, the FDA approved tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer that has progressed following prior chemotherapy.

FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
Article
Apr 29, 2024 7:58 PM
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.